Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-27 DOI:10.1080/14787210.2024.2334054
Alexis C Henderson, Preetam Cholli, Margaret A Lampe, Athena P Kourtis
{"title":"Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.","authors":"Alexis C Henderson, Preetam Cholli, Margaret A Lampe, Athena P Kourtis","doi":"10.1080/14787210.2024.2334054","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The HIV/AIDS epidemic has been one of the greatest challenges in global health, significantly affecting women of reproductive potential. Considerable advances in antiretroviral therapy for women living with HIV have contributed to improvements in quality of life, better reproductive and birth outcomes, and a reduced risk of perinatal transmission.</p><p><strong>Areas covered: </strong>Despite the progress made, persistent challenges in access and adherence to antiretroviral drugs may limit their benefits for some women. More pharmacokinetic and safety studies in pregnant and lactating women are urgently needed, as are prospective surveillance systems to evaluate associations between fetal and infant antiretroviral exposures, drug-drug interactions, and pregnancy outcomes.</p><p><strong>Expert opinion: </strong>Multipurpose technologies, such as combined HIV and other STI or unintended pregnancy prevention, and innovative delivery methods, such as the development of long-acting antiretrovirals, have the potential to reduce adherence challenges and enhance quality of life for women with HIV. Parallel advances in drug safety testing and surveillance are needed to ensure the health and safety of women with or at risk for HIV and children at risk for perinatal transmission.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287786/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2334054","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The HIV/AIDS epidemic has been one of the greatest challenges in global health, significantly affecting women of reproductive potential. Considerable advances in antiretroviral therapy for women living with HIV have contributed to improvements in quality of life, better reproductive and birth outcomes, and a reduced risk of perinatal transmission.

Areas covered: Despite the progress made, persistent challenges in access and adherence to antiretroviral drugs may limit their benefits for some women. More pharmacokinetic and safety studies in pregnant and lactating women are urgently needed, as are prospective surveillance systems to evaluate associations between fetal and infant antiretroviral exposures, drug-drug interactions, and pregnancy outcomes.

Expert opinion: Multipurpose technologies, such as combined HIV and other STI or unintended pregnancy prevention, and innovative delivery methods, such as the development of long-acting antiretrovirals, have the potential to reduce adherence challenges and enhance quality of life for women with HIV. Parallel advances in drug safety testing and surveillance are needed to ensure the health and safety of women with or at risk for HIV and children at risk for perinatal transmission.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
育龄妇女使用抗逆转录病毒药物的挑战、风险和机遇。
导言:艾滋病毒/艾滋病的流行是全球健康领域最大的挑战之一,对具有生育能力的妇女产生了重大影响。针对女性艾滋病毒感染者的抗逆转录病毒疗法取得了长足的进步,有助于提高生活质量,改善生殖和分娩效果,降低围产期传播风险:尽管取得了进展,但在获得和坚持使用抗逆转录病毒药物方面持续存在的挑战可能会限制这些药物给一些妇女带来的益处。亟需在孕妇和哺乳期妇女中开展更多的药代动力学和安全性研究,并建立前瞻性监测系统,以评估胎儿和婴儿的抗逆转录病毒暴露、药物间相互作用以及妊娠结局之间的关联:多用途技术,如艾滋病和其他性传播感染或意外怀孕的综合预防,以及创新的给药方法,如长效抗逆转录病毒药物的开发,都有可能减少感染艾滋病妇女在坚持用药方面遇到的挑战,并提高她们的生活质量。为确保感染艾滋病毒或有感染风险的妇女以及有围产期传播风险的儿童的健康和安全,需要在药物安全测试和监测方面取得同步进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
期刊最新文献
The opportunities and challenges of epigenetic approaches to manage herpes simplex infections. Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis ‎coinfection‎. Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. Is self-medication with antibiotics among the public a global concern: a mixed-methods systematic review. Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1